PARIS Feb 27 French drugmaker Ipsen
posted a full-year net loss of 29 million euros ($37.9 million)
on Wednesday that reflected its exit from the haemophilia
But the company said margins would remain stable in 2013 and
that sales of drugs prescribed by specialist doctors would
continue to grow.
The company said it expected sales of specialty care drugs
to rise between 6 and 8 percent this year, while revenue from
products prescribed by family doctors would decline between 6
and 8 percent as activity in France remains under pressure.
Ipsen is paying a flat dividend of 0.8 euros per share for
($1 = 0.7649 euros)
(Reporting by Benjamin Mallet and Elena Berton; Editing by